Introduction
Breast cancer is not a single disease, but rather, represents at least six subtypes (Perou et al., 2000; Sorlie et al., 2003; Hu et al., 2006) . These include luminal A, luminal B, normal-like, human epidermal growth factor receptor 2 (HER2)-enriched, claudin-low and basal-like, each with unique gene expression profiles and distinct clinical outcomes. The majority of breast cancer cases (60-80%) comprise the luminal/estrogen receptor-a positive (ERa þ ) tumors, whereas basal-like breast carcinoma accounts for 10-15% of all cases. The basal-like subtype, often clinically observed as 'triplenegative' tumors (negative for ERa, PR and HER2), is of particular interest because treatment options are limited to chemotherapy only and patients with this disease typically have poor outcomes. One contribution to the poor outcome of basal-like breast cancer patients may be their high cellular proliferation rates, which is manifested transcriptionally as the high expression of the 'proliferation signature'; this is a dominant gene signature that is a marker of cell proliferation rates across multiple tumor types (Hu et al., 2006; Whitfield et al., 2006) . B-Myb, a gene with known cell cycle control functions and implications in tumorigenesis (Sala, 2005) , is one of approximately 100 genes that define the proliferation signature.
B-Myb is a member of the vertebrate MYB family of nuclear transcription factors. In humans, this family is comprised of A-Myb (MYBL1), B-Myb (MYBL2) and c-Myb (MYB). Each family member is able to recognize and bind to the same DNA consensus sequence (PyAAC(G/T)G) to promote gene transcription; however, varying tissue-specific expression patterns, as well as protein-protein interactions with unique co-factors, suggest that distinct biological roles exist for each MYB family member (Rosinski and Atchley, 1998; Sala, 2005) . MYB proteins are encoded in the genomes of both plants and animals and control processes from flavonoid production to cellular proliferation (Rosinski and Atchley, 1998; Ito et al., 2001) . In contrast to vertebrates, invertebrates contain only one MYB protein, which in Drosophila (dMYB) is phylogenetically and functionally complementary to vertebrate B-Myb, suggesting B-Myb to be the most ancient family member (Davidson et al., 2005) . The expression of B-Myb, unlike c-Myb and A-Myb (Mucenski et al., 1991; Trauth et al., 1994; Toscani et al., 1997; Ness, 2003; Malaterre et al., 2007) , is ubiquitously expressed in virtually all proliferating cells as a regulator of cell cycle progression and plays an essential role in vertebrate development. Knocking out murine B-Myb causes early embryonic lethality (E4.5-6.5) resulting from unsuccessful inner cell mass formation (Tanaka et al., 1999) .
MYB family members have been implicated in tumorigenesis for several decades. The c-Myb protooncogene was first identified as the mammalian homolog of v-Myb, which is the transforming gene transmitted by the avian myeloblastosis and E26 retroviruses causing acute leukemia in birds (Klempnauer et al., 1982; Leprince et al., 1983) . A-and B-Myb were later discovered during low-stringency screening of human complementary DNA libraries (Nomura et al., 1988) . The B-Myb chromosomal locus, 20q13, is amplified and/or highly expressed in a variety of tumor types, including breast, prostate, liver and ovarian carcinomas, and in most cases this high expression portends a poor prognosis (Sala, 2005) . B-Myb is also an important marker of poor outcome in embryonal tumors of the central nervous system (Pomeroy et al., 2002) . Recently, a nonsynonymous B-Myb germline variant (rs2070235) causing a serine to glycine amino acid change (S427G) was linked to a decrease in overall cancer risk for neuroblastomas, chronic myelogenous leukemia and colon cancers in a combined dataset of cases and controls (Schwab et al., 2007) . However, the molecular roles of B-Myb in disease progression, as well as its transcriptional target genes in the mammary gland, are still poorly understood. To gain insight into B-Myb and its involvement in breast cancer, we analysed the expression of B-Myb across the breast cancer subtypes, examined its relationship to survival and pathological complete response, and the correlation of variant rs2070235 to disease risk. We also manipulated the expression of B-Myb and the S427G variant in normal and tumor-derived mammary cell lines and observed alterations in drug sensitivity and cell cycle profiles.
Results

High B-Myb expression in breast tumors predicts poor outcome
To assess the relevance of B-Myb gene expression across the breast cancer subtypes, breast tumor microarray data from the Netherlands Cancer Institute (NKI-295, n ¼ 295, van de Vijver et al., 2002) were analysed. Tumor samples were classified into five breast cancer subtypes using a single-sample centroid-based predictor as described (Hu et al., 2006) . An ANOVA (analysis of variance) analysis performed on these stratified samples showed that B-Myb expression differs significantly across the subtypes and was highest in basal-like tumors (Figure 1) .
To test for correlations between B-Myb mRNA expression alone and patient outcome, we analysed the NKI patients who were not receiving adjuvant systemic treatment (that is, local treatment only; n ¼ 165). This allowed us to identify the prognostic abilities of B-Myb better, without the confounding data of treatment response. The NKI 'local-only' tumors were rank ordered into halves (low/high) on the basis of their B-Myb expression levels and analysed for overall survival (OS) and relapse-free survival (RFS) by Kaplan-Meier analysis. Poor overall survival and RFS were highly correlated (Po0.001) with B-Myb high expression levels in these NKI samples (Figure 2a , and RFS data not shown). B-Myb expression alone was also able to significantly predict overall survival on localonly-treated luminal A subtype tumors (n ¼ 72) (Figure 2b ), luminal B subtype tumors (n ¼ 26) ( Figure 2c ) and HER2 þ /ERÀ subtype tumors (n ¼ 21) (Figure 2d ), but not basal-like tumors (n ¼ 30) (Supplementary Figure 1A) . We then evaluated the prognostic ability of B-Myb using two other published breast tumor microarray datasets (Miller et al., 2005; Wang et al., 2005) . Wang et al.'s (2005) study (n ¼ 286) consisted of microarrays on untreated, lymph-nodenegative primary ER þ and ERÀ breast cancers with relapse data, and B-Myb was capable of predicting RFS in these patients (Figure 2e ). On this same dataset, B-Myb also predicted RFS in the ER þ patient subset (n ¼ 209), but not in the ERÀ subset (n ¼ 77) (Supplementary Figures 1B and C) . Another dataset consisting of primary invasive tumors (Miller et al., 2005) (n ¼ 234) was tested and similar results were found (Figure 2f ).
To determine whether B-Myb expression was involved with pathological complete response, we used the data of Hess et al. (2006) , where microarrays were performed on pre-treatment breast tumors from patients receiving neoadjuvant paclitaxel, followed by 5FU-adriamycincyclophosphamide (T/FAC; n ¼ 133). Again, samples were split into two groups on the basis of B-Myb expression (low/high). B-Myb high expression was again associated with subtype (data not shown) and also with pathological complete response, as calculated by w 2 test (P ¼ 0.008; Supplementary Table 1 ).
B-Myb germline variant (rs2070235) increases the risk of basal-like breast cancer
A nonsynonymous germline B-Myb variant exists that causes a serine to glycine substitution (rs2070235, S427G). This non-conservative change prompted us to look for correlations between this variant and baseline susceptibility risk in the population-based Carolina Breast Cancer Study (CBCS) (Newman et al., 1995) . Odds ratios for the B-Myb genotype and all breast cancer cases, luminal A, and basal-like cases, versus controls are presented in Table 1 . There was no association between B-Myb genotype and all breast cancer cases (P ¼ 0.71); however, a statistically significant association was observed for basal-like breast cancer (P ¼ 0.047), but not for luminal A (P ¼ 0.14). No association was observed for B-Myb genotype and other breast cancer subtypes (luminal B, HER2 þ /ERÀ and unclassified: data not shown). Odds ratios were similar in African-Americans and Caucasians (likelihood-ratio tests for interaction with race were not statistically significant). Among controls in the CBCS, allele frequencies for the B-Myb G allele were higher in African-Americans (0.27) than in Caucasians (0.08).
Ectopic expression of B-Myb increases sensitivity to topoisomerase IIa inhibitors
Given B-Myb's expression within the proliferation signature, evidence suggesting that rapidly growing tumors may be more chemotherapy-sensitive and also the correlation between B-Myb expression and pathological complete response, we sought to determine whether ectopic expression of B-Myb in vitro had an effect on sensitivity to chemotherapeutics. B-Myb and the B-Myb S427G variant were overexpressed in two hTERT-immortalized human mammary epithelial cell lines (HME-CC, ME16C) and two basal-like tumorderived lines (SUM102, SUM149) (Supplementary Figure 2 ). Low endogenous B-Myb levels were detectable by western blot in the tumor lines, and in all cell lines by microarray analysis for mRNA levels (Supplementary Figure 2 and data not shown). All cell lines were also genotyped for rs2070235 and identified as homozygous for the major allele. It is important to note that the two normal tissue-derived cell lines have a basal-like phenotype when assessed by gene expression analysis (Troester et al., 2004) ; thus, these lines represent appropriate counterparts to the two basal-like tumor lines. Cells ectopically expressing B-Myb, or S427G variant, were treated with a panel of chemotherapy agents, including two DNA topoisomerase IIa (TOP2A) inhibitors (doxorubicin, etoposide), a DNA topoisomerase I inhibitor (camptothecin), a microtubule stabilizer (paclitaxel), a DNA alkylating agent (carboplatin) and an antimetabolite (5-fluorouracil), most of which are commonly used in breast cancer treatment. HME-CC cells overexpressing B-Myb, or the S427G variant, were approximately twice as sensitive to the two DNA TOP2A inhibitors, on the basis of IC50 assays, compared with the parental cell lines, but showed no significant change in sensitivity to the other drugs ( Figure 3a ). To further test B-Myb effects on chemotherapy sensitivity, another immortalized HMEC line (ME16C) and two basal-like tumor-derived cell lines (SUM102, SUM149) were tested. The ME16C cell line was also sensitized to TOP2A inhibitors by B-Myb expression, but not to treatment with other chemotherapeutics (Figure 3b and data not shown); however, this sensitivity profile was not observed in either of the two basal-like tumor-derived lines (Figures 3c and d) , where B-Myb expression had no apparent effect. The B-Myb S427G variant was also tested in each cell line for chemosensitivity, and it behaved similarly as the cells overexpressing wild-type B-Myb (Figure 3a and data not shown).
Gene expression analysis of cell lines ectopically expressing B-Myb
To look for gene expression changes in cells overexpressing B-Myb, and to further assess the chemotherapy phenotype, microarrays were performed on the HME-CC cell lines. Under normal, non-confluent conditions, the only statistically significant expression difference (significance analysis of microarrays (SAM) analysis (Tusher et al., 2001) with a 3% false discovery rate) was in B-Myb itself; also, no gene expression differences were observed between the B-Myb and B-Myb S427G-expressing cell lines. As a chemotherapy-related phenotype was observed in TOP2A inhibitors, we tested the cell lines after treatment with the 72-h IC50 dose of doxorubicin. In a two-class SAM analysis (that is, doxorubicin-treated HME-CC control versus doxorubicin-treated HME-CC þ B-Myb), 217 genes were identified (false discovery rate o3%; Supplementary Table 2 ).
An EASE (Expression Analysis Systematic Explorer) analysis (Hosack et al., 2003) was performed and many cell cycle-related gene ontology categories were identified as being significantly enriched (Table 2) . Therefore, in doxorubicin-treated cells overexpressing B-Myb, there was a significantly higher expression of many cell cycle genes compared with the treated control.
B-Myb is thought to be a transcriptional regulator of G2/M genes (Zhu et al., 2004) . To determine whether the 217-gene SAM list was enriched for genes within a particular phase of the cell cycle, each gene was assigned to a specific phase by comparing it with a known list derived from a precise cell cycle microarray time-course experiment (Whitfield et al., 2002) , or by literature search. Out of 217 significant genes, 101 genes were Figure 3) . At high doses of doxorubicin or etoposide, regardless of B-Myb expression, the majority of cells were arrested in G2/M phase.
Discussion
Clinically defined as ERÀ, PRÀ and HER2 not amplified, the basal-like subtype of breast cancer portends a poor prognosis. Basal-like breast cancer has an inherently high proliferation rate, which is identified by high expression of the 'proliferation signature' genes through microarray analysis; this signature has been identified in many tumor types, as per several publications, and is highly enriched for cell cycle-regulated genes (Whitfield et al., 2006) . Here, we find that B-Myb, a gene highly expressed within the proliferation cluster, plays an important role in regulating cell cycle progression, which likely has effects on patient prognosis and response to chemotherapy. We showed that B-Myb high expression was significantly associated with the poor outcome, basal-like breast cancer subtype, and that B-Myb gene expression levels alone predicted poor outcomes in the absence of therapy (that is, prognosis, Figure 2) , and are correlated with achieving a pathological complete response (that is, prediction, Supplementary Table 1 ). Stratification of B-Myb expression, even within the luminal A, B and HER2 þ /ERÀ subtypes, or ER þ tumors, was significantly associated with survival. Stratification of B-Myb expression within basal-like tumors did not predict outcomes, nor was outcome predicted in the ERÀ subset of the Wang et al. (2005) dataset (which includes basallike tumors); however, these are inherently poor-outcome tumors that significantly tend towards high B-Myb expression ( Figure 1) .
The B-Myb chromosomal locus, 20q13, is found amplified in a variety of cancers, including breast (Chin et al., 2006) , and this amplification is linked to poor prognosis (Bergamaschi et al., 2006) . Gene copy number analysis across breast tumor subtypes suggested that the genomic amplification of B-Myb was not enriched in the basal-like subtype, but instead was enriched in the luminal B subtype (Bergamaschi et al., 2006) . Therefore, within luminal tumors, B-Myb amplification and expression is an event that seems to be selected for and portends a poor prognosis (Figures 2b and c) . behavior of basal-like tumors, a subtype typical of chemo-responsiveness but with poor patient outcomes, has been described before and termed the 'basal-like tumor paradox' (Carey et al., 2006) , and the data presented here suggest that B-Myb might be a key regulator of this complex phenotype.
Recently, Schwab et al. (2007) linked the nonsynonymous B-Myb germline variant (S427G, rs2070235) to a decrease in overall cancer risk when combining neuroblastomas, chronic myelogenous leukemia and colon cancers into a single dataset and comparing this grouping of cases with non-cancer-bearing controls. While both studies are technically accurate (that is, similar allele frequencies in the control populations; CBCS: homozygous major allele 72.6%, heterozygous 24% and homozygous minor allele 3.4%; Schwab et al., 2007: 72.1, 27.3 and 0.4%, respectively) , the association of B-Myb rs2070235 genotype and basal-like breast cancer susceptibility differs from the earlier report and has not been described before. Here, in a populationbased case-control study, we found that the rs2070235 minor allele was associated with increased risk of basallike breast cancer but not other subtypes in the CBCS (Table 1 ). The discrepancy between the Schwab data and what is reported here may be due to differences between breast cancer and the cancers examined in the Schwab paper. Even among breast cancers there is significant heterogeneity across the subtypes in terms of the etiologic role of the B-Myb allele, and an analysis of breast cancer without subdivision would have missed the association of rs2070235 with the basal-like breast cancer subtype.
Presently, the function of the S427G variant is unknown. Our in vitro studies in breast epithelial cell lines showed neither a phenotypic difference between the overexpression of B-Myb or its variant on chemosensitivity relative to each other, nor did we observe a difference in their baseline gene expression patterns. It is temping to speculate that rs2070235 has functional consequences and somehow contributes to the etiology of basal-like tumors. The B-Myb variant was found to be nearly 10-fold more frequent in African-Americans (7%) than in non-African-Americans (0.8%) in the CBCS. This is relevant in light of recent data showing that premenopausal African-Americans are approximately twice as likely to develop basal-like tumors compared with premenopausal Caucasians (Carey et al., 2006; Millikan et al., 2008) . Of note, Schwab et al. (2007) showed that the B-Myb S427G protein was more stable than the wild-type protein. This increased stability may correspond to elevated B-Myb protein levels, possibly increasing transcriptional activity of G2/M cell cycle genes and leading to higher inherent proliferation rates. This alteration of cell cycle control may contribute to B-Myb's influence on poor outcome breast cancers. Additional assays are required to completely investigate the role of rs2070235 and other variants in B-Myb, which may also lie in linkage disequilibrium with the G allele. This is an important area of investigation, as it is possible that one or more variants in B-Myb could contribute to the higher frequency of basal-like breast cancer among African-American breast cancer patients and also to the pathophysiology of basal-like breast cancer.
As chemotherapy is currently the only option for basal-like cancer patients, we explored whether increased B-Myb expression had any effect on chemosensitivity in vitro. We observed a statistically significant increase in sensitivity to two TOP2A inhibitors, doxorubicin and etoposide, in the HME-CC and ME16C cells overexpressing B-Myb or its variant, but this phenotype was not observed in the basal-like tumorderived cell lines (Figure 3) . Also, there was no significant difference in chemosensitivity to the other tested drugs in any of the cell lines, which included camptothecin, a DNA topoisomerase I (TOP1) inhibitor. TOP2A, a nuclear enzyme that relaxes both negative and positive DNA supercoils by creating double-stranded DNA breaks, is of particular importance for proper DNA duplication during the S phase of the cell cycle (Smith et al., 1994) . TOP2A inhibitors cause the enzyme to become trapped on double-strand DNA breakpoints, thereby causing G2 cell cycle checkpoint arrest. As B-Myb is a G2/M regulating gene, increased B-Myb expression may be promoting the TOP2A-inhibitor-treated cells via the G2 checkpoint through induction of downstream B-Myb target genes. By facilitating cells through G2, with less regard for DNA damage, the B-Myb-overexpressing cells may attempt to cycle again, eventually leading to the observed increased sensitivity to TOP2A phenotype. TOP2A itself was on the B-Myb induced gene list (Supplementary Table 2 ), and thus more of the target of doxorubicin and etoposide was present, adding to the observed sensitivity phenotype in B-Myb-overexpressing cells.
In support of this hypothesis, the gene list identified by microarray analysis as being highly expressed in doxorubicin-treated, B-Myb-overexpressing cells (Supplementary Table 2 ) was significantly enriched in genes required for G2/M progression. For example, this list included the newly described B-Myb interacting protein LIN-9, a protein required along with B-Myb for the transcription of G2/M genes (Osterloh et al., 2007) . In addition, our B-Myb target gene list contained many B-Myb targets identified earlier, including CDC2, Cyclin B1 and BIRC5 (Zhu et al., 2004; Osterloh et al., 2007) . This gene list represents putative mammary B-Myb target genes and again suggests that B-Myb has its greatest effect on G2/M genes. In agreement with the gene list enrichment results, when B-Myb-overexpressing cells were treated with low doses of doxorubicin or etoposide, more cells accumulated in G1 versus controls, suggesting that the control cell line was appropriately inhibiting cell cycle progression at G2, whereas B-Myboverexpressing lines were bypassing this checkpoint ( Figure 5) .
The results of this study enhance our understanding of the role of B-Myb in breast cancer by identifying new B-Myb target genes, by showing that this gene is highly expressed in basal-like breast cancers and that it is of prognostic value for survival and predictive value for pathological complete response. Also, we have described a significant correlation between a B-Myb variant and an increased risk of basal-like breast cancer. These findings point to B-Myb as a biomarker that is of potential clinical importance for determining disease risk and for guiding treatment. In addition to its role in basal-like cancers, B-Myb may also be of great importance in luminal tumors, a breast cancer subtype with relatively good prognosis, as B-Myb expression was capable of stratifying the poor from the good actors within this group, and it is within this group where B-Myb is occasionally amplified on the DNA level. The link between B-Myb high expression and increased chemotherapy sensitivity in vitro is mirrored by similar findings in vivo where we and others have shown that basal-like tumors are, on average, the most sensitive to multi-agent chemotherapy regimens that contain an anthracycline (Rouzier et al., 2005; Carey et al., 2007) . It is unlikely that B-Myb expression alone is responsible for the chemotherapy sensitivity of basal-like tumors, but when coupled with the loss of TP53 function, which is known to occur in basal-like tumors (Sorlie et al., 2001) , and the loss of RB function (Derenzini et al., 2008; Herschkowitz et al., 2008) , multiple important checkpoints are deficient in basal-like tumors and it is this lack of control that may ultimately prove to be their Achilles' heel.
Materials and methods
Cell lines hTERT-immortalized, human mammary epithelial cell lines (HME-CC, ME16C) and basal-like breast cancer-derived lines (SUM102, SUM149) were cultured as described (Troester et al., 2004; Hoadley et al., 2007) . Full-length, human B-Myb complementary DNA (GenBank NM_002466) was cloned into the pBabe.puro.GWrfA (Gateway Reading Frame A) vector using Gateway Cloning Technology (Invitrogen, Carlsbad, CA, USA). Retrovirus was produced in Phoenix 293T cells by transfecting with 10 mg of vector using Lipofectamine 2000 (Invitrogen), as per the manufacturer's instructions. Media was changed 24 h after transfection and supernatants were collected 12 h later. Seventy-five micrograms of polybrene was added to the collected supernatants and applied to the mammary cell lines. Stable populations were selected by culturing in 1 mg/ml puromycin for HME-CC and ME16C, or 0.5 mg/ml puromycin for SUM102 and SUM149.
B-Myb variant (S427G) was created in the pBabe.puro.B-Myb expression vector using QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, Los Angeles, CA, USA).
Western blot analysis
Cells were grown in 10-cm tissue culture-treated dishes until 80% confluence, followed by harvest, protein isolation and quantification as described earlier (Troester et al., 2004) . Membranes were probed for B-Myb (sc-725; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and b-actin (AC-15; Abcam, Cambridge, MA, USA), followed by antirabbit or anti-mouse IgG horseradish peroxidase-linked whole antibody (Amersham Biosciences, Piscataway, NJ, USA) and detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA).
Cell cycle analysis
Cells were treated with a range of doxorubicin (0-70 nM) or etoposide (0-2 nM) doses and DNA content was analysed using a modified propidium iodide-staining assay. Briefly, one million cells were collected by trypsinization, washed in 1 Â PBS, and fixed in 70% ethanol at 4 1C overnight. Cells were washed with PBS/0.2% BSA and resuspended in 500 ml of PBS/0.2% BSA and 100 mg RNaseA. Propidium iodide was added to a final volume of 50 mg, and cells incubated at 37 1C for 30 min. DNA content analysis was performed using a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). To determine fractions of cells in G1 and G2/M phases, histograms of DNA content were analysed using Summit v4.3 software (Dako, Carpinteria, CA, USA) gating around 2 N and 4 N DNA content. Analyses were done on three separate days and mean values were calculated.
Cytotoxicity assay
Cell line sensitivities to drugs were assessed using a modified mitochondrial dye-conversion assay (Cell-Titer 96, Promega #G4100, Madison, WI, USA) as described (Troester et al., 2004; Hoadley et al., 2007) . Chemotherapeutics (carboplatin, doxorubicin, 5-fluorouracil, paclitaxel, etoposide, camptothecin) were purchased from Sigma (St Louis, MO, USA). The 72-h inhibitory concentration that caused a 50% reduction in MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) dye conversion (IC50) was determined using nonlinear regression (SAS Statistical Software, Cary, NC, USA) (Vanewijk and Hoekstra, 1993) . Differences in the IC50 estimates were tested. A traditional ANOVA test of nested models was performed using the R system for statistical computing (R Development Core Team, 2006, http://www. R-project.org).
Microarray analysis
Five replicates each of HME-CC B-Myb-overexpressing and vector control cell lines were treated with the 72-h IC50 dose of doxorubicin. Poly-A ( þ ) RNA was collected (Micro-Fast-Track2.0 mRNA Isolation Kit, Invitrogen) from treated control cells and B-Myb-overexpressing lines, reverse transcribed and labeled using the Agilent Low RNA Input Linear Amplification Kit (Agilent Technologies, Santa Clara, CA, USA), and hybridized to Agilent Human 44K Custom Oligo microarrays as described (Hu et al., 2005) . An untreated HME-CC cell line reference was co-hybridized to all arrays (for example, untreated HME-CC versus doxorubicin-treated empty vector HME-CC). Microarrays were scanned on an Axon Genepix 4000B microarray scanner and analysed using GenePix Pro 5.1 software (Molecular Devices, Sunnyvale, CA, USA). Data were normalized using Lowess normalization on the Cy3 and Cy5 channels. Microarray data are available at the UNC Microarray Database [http://genome.unc.edu] and at the Gene Expression Omnibus (GSE11429).
Microarray statistical analyses
Supervised microarray analysis was performed by selecting genes with an absolute signal intensity of at least 30 units in both dye channels and data present in at least 70% of experimental samples. A two-class, unpaired SAM was performed to identify significant genes associated with B-Myb expression with a false discovery rate of o3% (Tusher et al., 2001) .
The Netherlands Cancer Institute breast cancer dataset (NKI-295, n ¼ 295) was used for analysis of B-Myb expression across breast cancer subtypes (van de Vijver et al., 2002) ; however, only locally treated tumors (no chemotherapy) were used in survival analyses (n ¼ 165). Association of B-Myb expression states (rank ordered and split into halves: low/high) relative to survival was tested using the Cox-Mantel log-rank test and results visualized using Kaplan-Meier survival plots (WinSTAT v.2007.1) . Testing the association of B-Myb expression with subtypes was performed using ANOVA. Three other published datasets were analysed, as above, for survival (Miller et al., 2005; Wang et al., 2005) or pathological response (Hess et al., 2006) by w 2 using the R system for statistical computing.
B-Myb genotyping (CBCS)
The Carolina Breast Cancer Study is a population-based, casecontrol study of breast cancer conducted in 24 counties of central and eastern North Carolina between 1993 and 2001 (Newman et al., 1995; Millikan et al., 2003) . B-Myb genotyping (rs2070235) was conducted using DNA extracted from peripheral blood lymphocytes for 1256 cases with subtype information (500 African-American, 756 Caucasian) and 1814 controls (679 African-American, 1135 Caucasian). For complete details see Supplementary Materials.
